Olvi-Vec is an oncolytic immunotherapy with independent anti-tumor activity and generates responses to platinum chemotherapy in previously resistant tumors. Gynecologic Oncologists have long desired a platinum resensitizing agent. #Stage4NeedsMore #Biotech
About us
Genelux Corporation (NASDAQ: GNLX) is a late clinical-stage biotechnology company focused on improving the lives of patients affected by difficult-to-treat solid tumors. Our ChoiceTM Discovery Platform is the foundation of our oncolytic immunotherapy development, having produced over 500 different versions of the vaccinia virus. Olvi-Vec, our lead product candidate is currently in a Phase 3 registrational clinical trial for Platinum-Resistant/Refractory Ovarian Cancer (PRROC). Olvi-Vec is also being developed in Non-Small Cell Lung Cancer (NSCLC), recurrent Small Cell Lung Cancer (SCLC), and recurrent Ovarian Cancer. We are dedicated to advancing a pipeline of next-generation oncolytic immunotherapies that deliver the full complement of tumor neo-antigens with the power to stimulate a personalized immune response for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Information about our investigational products and clinical trials can be found here. For more information, please visit https://genelux.com/ and follow us on Twitter @Genelux_Corp and Facebook @Genelux. Olvi-Vec is an investigational product candidate not yet approved by the US Food and Drug Administration.
- Website
-
https://genelux.com/
External link for Genelux
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Westlake Village, California
- Type
- Public Company
- Founded
- 2001
Locations
-
Primary
Get directions
Westlake Village, California, US
Employees at Genelux
Updates
-
We are honored to be part of this great nation and are committed to serving our community with dedication and excellence. Cheers to 248 years of Independence. Happy 4th of July! #4thofjuly #independance
-
-
Our mission is to develop immunotherapeutics that deliver the full complement of tumor neo-antigens with the power to stimulate a personalized immune system response to fight cancer, individual by individual. Read more here: https://loom.ly/GNMHays #stage4needsmore
-
As we actively contribute to the collective effort in combating cancer, it is important to acknowledge and honor all the courageous cancer survivors during the month of June, recognized as #NationalCancerSurvivorAwarenessMonth. People are the heart and soul of our endeavors. The Genelux team is committed to advancing next-generation oncolytic immunotherapies, tailored to orchestrate a personalized, multi-faceted attack to overpower the intricate defense mechanisms of tumors. To all the brave cancer survivors, the Genelux family salutes you! #CancerSurvivor #CancerResearch #Stage4NeedsMore #Biotech #DrugResearch #Nasdaq
-
-
Did you know Olvi-Vec has been studied in multiple early and mid-phase clinical trials via regional and systemic deliveries, as a monotherapy and in combination with other therapies, in approximately 150 patients with a variety of cancer types? Visit the clinical trials page on our website to learn more: https://loom.ly/iSzGph8 #OvarianCancer #CancerResearch #Stage4NeedsMore #Biotech #Cancer #DrugResearch #Nasdaq
-
-
Are you eligible to participate in the OnPrime study? Check the eligibility criteria to see if you qualify. This trial is open to women diagnosed with platinum-resistant/refractory ovarian cancer, including fallopian tube and primary peritoneal cancer. Learn more here: https://loom.ly/dKh8gxQ #ClinicalTrialEligibility #OnPrimeStudy #OvarianCancerPatients #Stage4NeedsMore
-
-
Olvi-Vec is the most advanced clinical asset of our oncolytic virus technology platform. Olvi-Vec has a number of characteristics which we consider desirable in anti-tumor applications: - No genomic integration - Broad spectrum of activity - Robust lytic capabilities and high replication and proliferation - Powerful immune activator (Th1-type immune response) - Driver of tumor microenvironment conversion from a “cold” to a “hot” state Along with our data showing the ability to reverse platinum resistance and be delivered systemically, Olvi-Vec is primed to be the potential leader in the space. #Stage4NeedsMore #DrugResearch #Nasdaq #HealthcareInvesting #BiotechInnovation
-
Genelux was thrilled to partner with Clearity Foundation for an insightful discussion around Platinum Sensitive/Resistant/Refractory Ovarian Cancer treatment options and clinical trials. Watch the full event now, https://loom.ly/uG8UnLg. #CancerResearch #Stage4NeedsMore #Cancer
Platinum Resistant Refractory Ovarian Cancer - Despite limited options, there is reason for hope
https://www.youtube.com/
-
Genelux reposted this
With a currently enrolling Phase 3 trial aimed at improving outcomes in this patient population, we recognize that #Stage4NeedsMore. For more information on the clinical trial, click link in bio or go to https://ow.ly/ynbo50RPCbQ. #clinicaltrials #GOGF #GOGPartners #ovariancancer #NCRM24
-
Progression-free survival (PFS) is a critical clinical endpoint in cancer research and treatment, providing valuable information about the effectiveness of a therapeutic intervention. PFS refers to the duration of time during and after treatment when a patient's disease does not progress or worsen. The significance of PFS lies in its ability to serve as a surrogate marker for the overall efficacy of a treatment regimen. It is a key measure in clinical trials and is often used to assess the impact of new drugs or therapies on disease control. Longer PFS may be associated with better clinical outcomes and improved quality of life for patients. Genelux is using PFS as the primary end point in its ongoing Phase 3 OnPrime/GOG-3076 trial as we look to have a direct impact on the well-being and quality of life for individuals facing cancer and replicate our data from the completed VIRO-15 trial. #cancerresearch #stage4needsmore #cancer #lungcancer #lungcancerawarenessmonth